<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01399632</url>
  </required_header>
  <id_info>
    <org_study_id>HL095964</org_study_id>
    <nct_id>NCT01399632</nct_id>
  </id_info>
  <brief_title>Dietary Fat and High-Density Lipoprotein (HDL) Metabolism-Effect of Carbohydrate and Fat Intake</brief_title>
  <official_title>Dietary Fat and High-Density Lipoprotein (HDL) Metabolism-Effect of Carbohydrate and Fat Intake</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Generally, people with low levels of high-density lipoprotein (HDL) in blood are more likely&#xD;
      to get heart disease than those who have normal or high levels. Dietary fat, whether the&#xD;
      harmful type (saturated) or beneficial type (unsaturated) raises HDL levels. Dietary&#xD;
      carbohydrate lowers HDL. The investigators are doing this research study to find out why the&#xD;
      amount of HDL in a person's blood is affected by dietary unsaturated fat and carbohydrate.&#xD;
      The investigators will trace the ability of the HDL in a person's blood to take up&#xD;
      cholesterol, get bigger, and then leave the blood by passing into the liver. The&#xD;
      investigators want to know if dietary unsaturated fat improves the ability of HDL to do this&#xD;
      compared to dietary carbohydrate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will study the kinetics of multiple types of high-density lipoprotein (HDL)&#xD;
      in humans under two strictly controlled dietary conditions, high unsaturated fat and high&#xD;
      carbohydrate, in 20 individuals with low HDL cholesterol and overweight or obesity. The&#xD;
      participants will be given the controlled diets for 4 weeks in a randomized crossover design.&#xD;
      They will be admitted to the Brigham &amp; Women's Hospital Center for Clinical Investigation&#xD;
      (CCI) the morning of Day 28 when they will be infused intravenously with a stable isotope&#xD;
      tracer, trideuterated (D3), leucine for 10 minutes as a bolus. Blood will be sampled in the&#xD;
      hospital through 24 hours, and thereafter at the ambulatory clinical center throughout 94&#xD;
      hours. HDL subtypes will be prepared in Dr. Sacks's laboratory at Harvard School of Public&#xD;
      Health (HSPH) and analyzed for content of lipids and proteins, and for incorporation of the&#xD;
      tracer into apolipoprotein A-I, the principal protein of HDL. These data will be studied by&#xD;
      interactive modeling to a multi-compartment model of human HDL physiology that best fits the&#xD;
      observed data. The model will yield HDL metabolic rates during unsaturated fat and&#xD;
      carbohydrate-rich diets which will be tested for statistical significance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>high-density lipoprotein (HDL) cholesterol</measure>
    <time_frame>Diet Periods I and II-Days 28-32</time_frame>
    <description>To determine how dietary unsaturated fat when it replaces carbohydrate affects HDL metabolism.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To study HDL with apoE</measure>
    <time_frame>Diet Periods I and II-Days 28-32</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Provide guidance for interpreting effects of unsaturated fats on reverse cholesterol transport</measure>
    <time_frame>Diet Periods I and II-Days 28-32</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Overweight</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>High Fat and Low Carbohydrate Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Fat and High Carbohydrate Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low Fat and High Carbohydrate Diet</intervention_name>
    <description>Low Fat and High Carbohydrate Diet</description>
    <arm_group_label>Low Fat and High Carbohydrate Diet</arm_group_label>
    <other_name>Diet and HDL Metabolism</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>High Fat and Low Carbohydrate Diet</intervention_name>
    <description>High Fat and Low Carbohydrate Diet</description>
    <arm_group_label>High Fat and Low Carbohydrate Diet</arm_group_label>
    <other_name>Diet and HDL Metabolism</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Only accepting participants in the Boston, Massachusetts area&#xD;
&#xD;
          -  Age 21 to 75, male or female&#xD;
&#xD;
          -  Willingness to eat prescribed diet for 4 weeks prior to infusion date, and 3.5 days&#xD;
             after the infusion date&#xD;
&#xD;
          -  Willingness to participate in an infusion protocol, which will require them to stay at&#xD;
             the Center for Clinical Investigation (CCI) for one night and return for blood draws&#xD;
             every day for the next 3 days.&#xD;
&#xD;
          -  Body Mass Index (BMI) 25-35 Kg/m2&#xD;
&#xD;
          -  HDL&lt;45 mg/dL for men, &lt;55 mg/dL for women&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hematocrit &lt;33&#xD;
&#xD;
          -  Low-density Lipoprotein (LDL) cholesterol &gt;190 mg/dl&#xD;
&#xD;
          -  HDL cholesterol &lt;20 mg/dl, to exclude those with rare genetic HDL deficiency syndromes&#xD;
&#xD;
          -  Fasting Triglycerides &gt;500 mg/dl to exclude those with risk of pancreatitis&#xD;
&#xD;
          -  ApoE genotypes, E2E2, E2E4, and E4E4.&#xD;
&#xD;
          -  Lipid lowering medications&#xD;
&#xD;
          -  Hormone replacement therapy&#xD;
&#xD;
          -  Other medicines that affect plasma lipid levels: e.g. beta blockers, certain&#xD;
             psychiatric medicines including Alprazolam, Chlordiazepoxide, Clonazepam, Diazepam,&#xD;
             Lorazepam, Oxazepam, Prazepam, Aripiprazole, Chlorpromazine, Chlorprothixene,&#xD;
             Clozapine, Flupenthixol, Fluphenazine, Haloperidol, Loxapine, Mesoridazine,&#xD;
             Methotrimeprazine, Molindone, Olanzapine, Perphenazine, Pimozide, Pipotiazine,&#xD;
             Prochlorperazine, Promazine, Promethazine, Quetiapine, Risperidone, Sulpiride,&#xD;
             Thioridazine, Thiothixene, Trifluoperazine, Ziprasidone.&#xD;
&#xD;
          -  Thyrotrophin-stimulating hormone: &lt;0.5 or &gt;5.0&#xD;
&#xD;
          -  alanine aminotransferase : 1.5 x uln or 60 IU/L&#xD;
&#xD;
          -  Aspartate transaminase: 1.5 x uln or 60 IU/L&#xD;
&#xD;
          -  Bilirubin: outside upper limit. (&gt;1.2 mg/dL)&#xD;
&#xD;
          -  Creatinine: outside upper limit (&gt;1.00 mg/dL)&#xD;
&#xD;
          -  Diabetes by history&#xD;
&#xD;
          -  Diabetes by fasting or post-challenge glycemia according to ADA guidelines:&#xD;
&#xD;
               -  Fasting hyperglycemia (glucose &gt;126 mg/dl).&#xD;
&#xD;
               -  Post-challenge glucose by standard oral glucose tolerance test, &gt;200 mg/dl&#xD;
&#xD;
          -  Will not eat the provided diet and abstain from alcoholic beverages.&#xD;
&#xD;
          -  Women who are pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank M Sacks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harvard T. H. Chan School of Public Health</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>July 15, 2011</study_first_submitted>
  <study_first_submitted_qc>July 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2011</study_first_posted>
  <last_update_submitted>July 5, 2016</last_update_submitted>
  <last_update_submitted_qc>July 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Frank M. Sacks</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

